+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Stroke and antiphospholipid syndrome-antiphospholipid antibodies are a risk factor for an ischemic cerebrovascular event



Stroke and antiphospholipid syndrome-antiphospholipid antibodies are a risk factor for an ischemic cerebrovascular event



Clinical Rheumatology 38(2): 379-384



Testing for antiphospholipid antibodies could be an important part in determining the cause of a cerebrovascular event (CVE). Currently, it is also unknown whether antiphospholipid antibodies represent a risk factor for the development of a CVE and whether the selected therapy options are efficacious. So, this study aimed at (1) determining the frequency of patients experiencing a CVE and fulfilling the laboratory criterion for an antiphospholipid syndrome (APS), (2) investigating whether the persistent presence of antiphospholipid antibodies represented a risk factor for a CVE, and (3) focusing on the efficacy of the selected treatment strategy in the first year after the CVE. Eighty-nine patients with an acute CVE were prospectively followed for 1 year. At least two sera from each were tested for lupus anticoagulants, anticardiolipin, anti-β2-glycoprotein I, anti-phosphatidylserine/prothrombin and anti-annexin V antibodies. Twenty out of eighty-nine (22%) of CVE patients fulfilled the criteria for APS (17/20 for definitive and 3 for probable APS). There was a significant association between persistently present antiphospholipid antibodies and the CVE (OR, 4.62). No statistically significant difference was found in the CVE recurrence rate between APS-CVE and non-APS-CVE patients being treated mainly with acetyl salicylic acid. Antiphospholipid antibodies represent an independent risk factor for a CVE. In the first year after the CVE, antiplatelet therapy seemed to be sufficient in secondary CVE thromboprophylaxis in most APS patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065536937

Download citation: RISBibTeXText

PMID: 30088114

DOI: 10.1007/s10067-018-4247-3


Related references

FRI0425The Global Antiphospholipid Syndrome Score (GAPSS) Differentiates Between Transient Ischemic Attack and Stroke in Patients with Antiphospholipid Antibodies. Annals of the Rheumatic Diseases 74(Suppl 2): 581.1-581, 2015

Antiphospholipid syndrome without antiphospholipid antibodies at the time of the thrombotic event: transient 'seronegative' antiphospholipid syndrome?. Clinical and Experimental Rheumatology 15(5): 541-544, 1997

Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Neurology 43(10): 2069-2073, 1993

Clinical, radiological, and pathological aspects of cerebrovascular disease associated with antiphospholipid antibodies. The Antiphospholipid Antibodies in Stroke Study Group (APASS). Stroke 24(12 Suppl.): I120-I123, 1993

Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 31(6): 1283-1288, 2000

Antiphospholipid antibodies: a risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the 'primary' antiphospholipid syndrome. Annals of the Rheumatic Diseases 48(5): 358-361, 1989

Factor v Leiden and antiphospholipid antibodies in either mothers or infants increase the risk for perinatal arterial ischemic stroke. Stroke 40(1): 65-70, 2009

Sneddons syndrome with antiphospholipid antibodies and primary antiphospholipid syndrome with cerebrovascular disease. Journal of Autoimmunity 15(2): A7, 2000

Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. The Antiphospholipid Antibodies in Stroke Study Group. Stroke 23(2 Suppl): I29-I32, 1992

Transient disappearance of serum antiphospholipid antibodies during the course of a thrombotic event in two adolescents with antiphospholipid syndrome receiving prednisone. Clinical and Experimental Rheumatology 12(4): 460-461, 1994

Antiphospholipid antibodies in neonates with stroke--a unique entity or variant of antiphospholipid syndrome?. Lupus 23(10): 986-993, 2014

Antiphospholipid antibodies correlate with stroke severity and outcome in patients with antiphospholipid syndrome. Autoimmunity 48(5): 275-281, 2015

Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome. Annals of the Rheumatic Diseases 67(3): 395-401, 2008

Antiphospholipid antibodies and the risk of thrombosis: a comparative survey between chronic immune thrombocytopenia and primary antiphospholipid syndrome. La Revue de Medecine Interne 32(12): 724-729, 2011

Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus 14(2): 129-136, 2005